Skip Navigation

European Heart Journal 1999 20(9):645-652; doi:10.1053/euhj.1998.1339
Copyright © 1999 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sätre, H.
Right arrow Articles by Wallentin, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sätre, H.
Right arrow Articles by Wallentin, L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Reduction of myocardial damage by prolonged treatment with subcutaneous low molecular weight heparin in unstable coronary artery disease

H. Sätrea, L. Holmvangb,f1, G.S. Wagnerc, B. Lindahld and L. Wallentind

a Department of Cardiology, Falun Hospital, Falun, Sweden
b The Heart Center, Rigshospitalet, Copenhagen, Denmark
c Duke University Medical Center, Division of Cardiology, Durham, North Carolina, U.S.A.
d Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden

revised September 28, 1998; accepted September 30, 1998

Abstract

Aims

Several studies have proved heparin useful in treating patients with unstable coronary artery disease. The present study investigates whether Selvester QRS scoring for estimation of myocardial infarct size increases the incidence of detection of acute myocardial infarction during follow-up in a trial of patients with unstable angina/non-Q wave myocardial infarction treated with low molecular weight heparin or placebo. Finally it will be discussed how the QRS score, used for end-point identification, impacts on the power calculation in clinical trials.

Methods and Results

Electrocardiographic data on 1276 patients (644 in the placebo group, 632 in the low molecular weight heparin treatment group) were available. All ECGs were scored according to the Selvester QRS scoring method. At 40 days, more patients in the placebo than in the heparin group had achieved a threshold level of QRS score (25·9% vs 21·1%,P=0·05). Myocardial infarction, diagnosed as per the classic Q wave criteria, occurred in 3·7% of patients in the placebo group and in 0·9% in the low molecular weight heparin group at 6 days (P=0·002). At 40 days, the rates were 8·2% (placebo) and 5·7% (low molecular weight heparin,P=0·2). By combining the classic criteria with the Selvester method the myocardial infarction end-point rate in both groups was almost doubled (8·2% to 14·4% in the placebo group and 5·7% to 11·1% in the low molecular weight heparin group,P=0·07). The 216 patients with non-evaluable electrocardiograms did not differ from the 1276 patients as regards baseline characteristics; however, they had a significantly poorer prognosis, with a death/myocardial infarction rate of 20% at 40 days, compared with 8% among the patients with evaluable electrocardiograms (P<0·00001).

Conclusion

Long-term subcutaneous treatment with low molecular weight heparin decreases the number of subsequent myocardial infarctions—determined both conventionally and by an increase in QRS score—in patients with unstable coronary artery disease. Silent myocardial infarctions detected by QRS score, as well as clinical myocardial infarctions, could be used as end-points in clinical trials of ischaemic heart disease and thus lower the population needed for obtaining statistical power.

Key Words: Low molecular weight heparin • unstable angina • myocardial infarction • QRS score • statistical power

f1 Correspondence: Lene Holmvang, MD, The Heart Center 2141, Rigshospitalet, 2100 Copenhagen Ø, Denmark


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
L. Holmvang, P. Clemmensen, B. Lindahl, B. Lagerqvist, P. Venge, G. Wagner, L. Wallentin, and P. Grande
Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment
J. Am. Coll. Cardiol., March 19, 2003; 41(6): 905 - 915.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.